# Neurogenetics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurogenetics

- Industry: Healthcare
- Headquarters: US
- Total disclosed funding: $62M
- Latest round: Series C (Oct 19, 2005)
- Investors on record: 10

## About

Neurogenetics is a biopharmaceutical company that focuses on the development of novel small molecule therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders.

## Funding rounds

- Series C, Oct 19, 2005, $35M — Advent International, Alta Partners, Sorrento Ventures, Novartis Venture Fund, Gimv, Daiwa Corporate Investment, SR One, Johnson & Johnson Innovation, Alta Biopharma
- Series B, Oct 29, 2002, $10M — Advent International, Alta Partners, Novartis Venture Fund, Gimv, SR One, Eisai Co
- Series B, Jun 25, 2001, $9M — Advent International, Alta Partners, Novartis Venture Fund, Gimv, SR One
- Series A, Sep 27, 2000, $8M — Advent International, Alta Partners, Gimv

## Investors

- Advent International (https://capitalatlas.ai/funds/advent-international) — Series A, Series B, Series C
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A, Series B, Series C
- Gimv (https://capitalatlas.ai/funds/gimv) — Series A, Series B, Series C
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B, Series C
- SR One (https://capitalatlas.ai/funds/sr-one) — Series B, Series C
- Eisai Co — Series B
- Sorrento Ventures (https://capitalatlas.ai/funds/sorrento-ventures) — Series C
- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series C
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series C
- Alta Biopharma — Series C